-
Mashup Score: 1
The survival benefit with dostarlimab/chemotherapy was deemed unprecedented in patients with microsatellite instability high primary advanced or recurrent endometrial cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Results from the KEYNOTE-868 trial showed a favorable benefit of pembrolizumab plus chemotherapy across endometrial cancer subgroups.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Latest analysis of the results from the DUO-E Phase III trial showed IMFINZI ® (durvalumab) plus platinum-based chemotherapy followed by IMFINZI plus LYNPARZA ® (olaparib) (LYNPARZA and IMFINZI arm) demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone. These results will be presented today in a late-breaking session at the 2024 Society of Gynecologic
Source: www.astrazeneca-us.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 312024 SGO Winter Meeting - 2 month(s) ago
Explore this photo album by Society of Gynecologic Oncology/Foundation for Wom on Flickr!
Source: www.flickr.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 312024 SGO Winter Meeting - 2 month(s) ago
Explore this photo album by Society of Gynecologic Oncology/Foundation for Wom on Flickr!
Source: www.flickr.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 302024 SGO Winter Meeting - 2 month(s) ago
Explore this photo album by Society of Gynecologic Oncology/Foundation for Wom on Flickr!
Source: www.flickr.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4SGO Allied Health Professionals Meeting - 7 month(s) ago
Explore this photo album by Society of Gynecologic Oncology on Flickr!
Source: www.flickr.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The SGO 2023 Allied Health Professionals Meeting is wrapping up! What a phenomenal weekend it has been, filled with inspiring talks, valuable insights, and meaningful connections. Thank you to everyone here who made the event possible. See photos https://t.co/cydLyVin6v. #SGOMtg https://t.co/4n8zAi3ea4
-
-
Mashup Score: 0Registration | Society of Gynecologic Oncology - 7 month(s) ago
This year’s conference will be in-person only. No virtual option will be available for this conference. On or Before July 28, 2023 After July 28, 2023 To save money on registration, apply for SGO membership by contacting membership@sgo.org. REGISTRATION CANCE LLATION POLICY: Cancellation requests submitted to meetings@sgo.org on or before July 28, 2023, will receive a full refund less a $100 USD administration fee. After July 28, 2023, there will be no refunds granted for any cancellations or for
Source: www.sgo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Allied Health Professionals Meeting | SGO - 7 month(s) ago
Join us for the Society of Gynecologic Oncology (SGO) 2023 Allied Health Professionals Meeting, Sept. 8 – 10 in Phoenix, AZ! This meeting is specially designed for nurse practitioners, physician assistants/physician associates, registered nurses, physicians, and other members of the gynecologic oncology care team. Wound Assessment and Treatment: Focus on the Surgical Wound Beyond Kegels and Dilators: Pelvic Health Physical Therapy for the Oncology Patient Goals of Care Discussion for the Advance Practice
Source: www.sgo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The combination of dostarlimab plus carboplatin/paclitaxel demonstrated a 31% improvement in OS vs placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer, irrespective of MSI status. #SGOMtg | @SGO_org @matthewapowell https://t.co/EqFRwjKt76